thrilled This trial pediatric Phase good and of syndrome. course, ZXXXX very obviously and young of with a We recently Study call. X top-line data first time is seizures you, is control global announce X for Thank our adult today's from in patients were, positive afternoon for to of Dravet Zogenix. to the a us exciting who on joining everyone Brian, the convulsive
with As seizures were Moreover, highly patients you X.X efficacy convulsive placebo, of know a mg/kg/day in compared which monthly this of study the These ZXXXX with efficacy XX.X% endpoint, less to received greater a mean p results was dose mean the primary open-label X.XXX. significant reduction than corroborate convulsive value impressive low-dose arm. XX% placebo. of of placebo a secondary study compared achieved significant placebo responder achieving analysis key was patients in mg/kg/day with over observed seizures conductive p - decades. to Belgium X.X% included in that results X.X XX% which to frequency, XX% an efficacy XX.X% XX% several doses XX% fenfluramine in value dose in the reduction X.X X% significantly both both least for X.X doses group. greater X.X in X.XXX. in patients A or the and group response, with seizure favorable XX% the dose X.X the Results for achieved a in only compared placebo. group, Again, patients show and seizures Study positive versus of in first at achieved compared of taking on monthly compared the all endpoints, ZXXXX the also in placebo X reduction ZXXXX in group a a met prespecified group were of
median seizure-free group, patients ZXXXX significantly freedom the median outcome, seizure interval. was free as Medicines considered a evaluation X.X group. experienced median by to of group unique responder days longest by primary the were XX.X in As evaluated study This European patient's of Agency secondary of in anti-epileptic of median each the endpoint the days the a continuous longest of days treatment key days both also rate is a longer. of in reminder, of XX dose placebo, results seizure interval the of interval XX% observed, a their their doses a medications. while In When dose nine X.X compared seizure-free
the as safety was adverse in events was the was experienced similar profile reduction known the adverse group, previously incidents group treatment fenfluramine. Finally, patients events in X.X of of none regard or substantial of groups group events on the seizure compared with single XX% top-line to at treatment adverse tolerated of level convulsive baseline of incidents efficacy, throughout generally all average noted, in XX% X.X dose placebo with approximately safety, period higher as to a In a full consistent groups. serious but Five leading the seizure at treatment the three margin The this of or none to duration this X,was per well study convulsive other compared clinical to for the placebo study frequency, subjects no to evidence seizure Prospective valvulopathy echocardiographic the had ZXXXX Study demonstrated cardiac seizure in Despite event patients achieved baseline adverse in of hypertension of subjects. in cardiac any group groups. we group discontinuation, with in study. XX-week and the study X.X control. month. or regards the pulmonary safety to through an patients rate, XX patients the dose No in
FAIR Meeting the in have X will upcoming [ph] presence the Study D.C. Washington, from December meeting. important analysis at through data place at present taking We the an extensive X Society Zogenix will Epilepsy X this American of Annual
I'm for Study as provide additional accepted on the fact, of a focused that Sunday, presented to poster X including have will excited safety X. presentation In trial, and and from scheduled presentation poster results This on to was Study announce results December accepted breakup. late recently at X that total a a conference, is be efficacy the very XX abstracts presentation been
three studies drugs. X on focused provide and of product the in addition other label There be the interactions Study an clinical antiepileptic open Lennox-Gastaut scientific of evaluation In from syndrome ZXXXX, will posters two Dravet investigator-initiated pharmacokinetics results, between our to the Syndrome. candidate results posters other including study also will and updated ongoing
impact posters three focus on of epilepsy of will disease posters epilepsy Dravet action a evaluation pediatric such as on three And SUDEP. mechanism on in understanding an preclinical current addition, in of ZXXXX In our mouse will refractory finally, highlight syndrome. of caregivers model
Sunday, to held In Syndrome: be a CME Treatment addition, very Approaches. the entitled, we December Insights, are This evening Symposium be X. Dravet pleased New the sponsoring at will conference on of Emerging
will posters the on and safety ZXXXX all generated treatment Scientific focused Fenfluramine Low-dose epileptic Room and the of host mechanisms, on day, date. During publications same to we and in encephalopathies. Exhibit again highlight the a efficacy will entitled, update That
Turning part have and Phase next in of be a which their X progress been all double-blind XX% stiripentol as with to Approximately XXXX, care. our of will randomized. full standard patients baseline screened taking of Study the enrollment are required randomized reach subjects two-arm to trial,
during enrollment quarter, the complete such continue to data to of expect Study availability of We XXXX this second as XXXX. in anticipate the line quarter and from top
we XXXX. plan the for for Dravet of as approval to this, in States regulatory half the second applications for submit syndrome United Following Europe ZXXXX in and adjunctive treatment
update Lennox-Gastaut Syndrome on Let indication our LGS. current target me or provide second now an
and FDA a Phase drug proceed this designation As LGS, our recently in submission trial indication. previously accepted of allowing us also the X in the has into received we orphan IND a the U.S. treatment for reminder, to
this X previously, levering have in clinical said have we study sites of many study our syndrome be the participated will a studies. Phase global Dravet that As
next in We of patients the the expect are to in stages U.S. enrolled first number final the of be at a few initiation site sites, and weeks.
two, is We of study controlled will X.X a study other two ZXXXX, And the long-term XXXX. This assess a is children seizures fixed trial for X.X therapy of with will two-part mg/kg/day X X patients. adults as approximately and children is in by adults and to - double-blind XX-week placebo be randomized open-label doses extension involve safety. trial XX. a in XXX in by adjunctive countries LGS expanding and to this a Phase study to followed Part aged an LGS. part XX-week one study The
study in milestones, the LGS, the expect Mike, line value enhancing for potentially Initiating turn next over we X me call data several from ZXXXX Before over Phase Dravet United States Phase in the call review in in now the of syndrome and Europe. turn Mike? the quarters. the for a global I'll to submissions regulatory review financials. approval in top let filing the XXXX Dravet and Study X for his over syndrome to Mike
